Want to see GDRX full AI Analyst Report?
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.GoodRx is shifting its expense mix toward operating leverage: marketing spend has come down and appears more efficient (supporting subscription momentum), product development remains steady to fuel Pharma Direct and e‑commerce expansion, and G&A stays controlled—helping push adjusted EBITDA higher. At the same time rising depreciation & amortization suggests past investments/acquisitions and retail/e‑commerce buildouts are increasing noncash charges, which can depress GAAP profit even as underlying margin and growth metrics improve.
Date | Sales and Marketing | General and Administrative | Depreciation and Amortization | Product Development and Technology |
|---|---|---|---|---|
Jun 30, 2026 | $81.99M | $24.81M | $22.27M | $26.71M |
Mar 31, 2026 | $81.05M | $26.82M | $21.79M | $30.18M |
Dec 31, 2025 | $78.62M | $23.94M | $23.15M | $28.94M |
Sep 30, 2025 | $83.53M | $32.01M | $21.43M | $31.01M |
Jun 30, 2025 | $84.87M | $28.38M | $19.73M | $29.93M |
Mar 31, 2025 | $84.54M | $29.63M | $20.91M | $31.14M |
Dec 31, 2024 | $93.83M | $23.55M | $19.10M | $31.74M |
Sep 30, 2024 | $89.87M | $25.62M | $17.54M | $30.14M |
Jun 30, 2024 | $93.45M | $27.59M | $16.96M | $30.85M |
Mar 31, 2024 | $89.96M | $41.11M | $15.94M | $31.02M |